Phase II Trial of Opaganib Addition in Metastatic Castration‐Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide
Open Access
- 14 April 2026
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71633
Abstract
Introduction: Opaganib is a first‐in‐class oral sphingolipid metabolism inhibitor that inhibits sphingosinekinase 2 (SphK2) and dihydroceramide desaturase (DES) and that has a demonstrated safety and preliminary anti‐cancer activity signal in a Phase I study. Methods: In this phase II trial, patients with metastatic castration‐resistant prostate cancer who had disease progression on novel hormonal agents (NHAs) abiraterone or enzalutamide were enrolled and treated with opaganib while continuing their NHA. After safety lead‐in cohorts, the trial enrolled cohort 2 (abiraterone + opaganib 500 mg Q 12 h) and cohort 3 (enzalutamide + opaganib 500 mg Q 12 h). The primary efficacy endpoint was the proportion of patients with disease control at Day 113. The postulated disease control rate was 10%. Secondary efficacy endpoints include prostate‐specific antigen (PSA) progression‐free survival (PSA‐PFS) and PSA response rates. The primary safety endpoint was the incidence of adverse events (AEs). Results: The disease control rates were 15% (95% CI = 4%–35%, 4 of 26 patients) in cohort 2 and 9% (95% CI = 2%–24%, 3 of 34 patients) in cohort 3. The median PSA‐PFS was 56 days (95% CI = 35–112 days) in cohort 2 and 55 days (95% CI = 35–56 days) in cohort 3. The most common AEs of grade 3 or higher were hypertension (8%) and musculoskeletal AEs (8%) in cohort 2 and grade 3 anemia (18%) in cohort 3. Conclusion: The trial did not meet its primary objective of demonstrating 30% disease control at 113 days. However, subjects who experienced a PSA response or stabilization warrant further exploration for biomarkers of response. Trial Registration: ClinicalTrials.gov number: NCT04207255Keywords
Funding Information
- National Cancer Institute (P01 CA203628‐07A1; B. Ogretmen, PI)
- RedHill Biopharma
This publication has 47 references indexed in Scilit:
- 1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)Annals of Oncology, 2023
- Liquide sous-rétinien associé aux inhibiteurs de MEK et BRAFJournal Français d'Ophtalmologie, 2022
- Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseEBioMedicine, 2021
- Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor–Associated RetinopathyJAMA Ophthalmology, 2021
- Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical TrialEuropean Urology Oncology, 2019
- Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate CancerEuropean Urology, 2016
- Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic CancerJAMA Ophthalmology, 2016
- Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advancesProgress in Lipid Research, 2016
- Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapyExperimental Cell Research, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009